NASDAQ:AMLX

Amylyx Pharmaceuticals Stock News

Healthcare > Biotechnology

Buy AMLX

*Your capital is at risk

$13.20

-0.0900 (-0.677%)

At Close: Jun 03, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation

10:00am, Sunday, 18'th May 2025

NEW YORK CITY, NY / ACCESS Newswire / May 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Comp

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation

10:00am, Thursday, 15'th May 2025

NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Comp

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out

10:00am, Tuesday, 13'th May 2025

NEW YORK CITY, NY / ACCESS Newswire / May 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Comp

Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome

07:00am, Monday, 12'th May 2025

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out

10:00am, Sunday, 11'th May 2025

NEW YORK CITY, NY / ACCESS Newswire / May 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Comp

Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2025 Earnings Call Transcript

11:19am, Saturday, 10'th May 2025

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Lindsey Allen - Vice President Investor Relations and Communications Justin Kle

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect

10:00am, Thursday, 08'th May 2025

NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Compa

Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results

07:00am, Thursday, 08'th May 2025

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals reports First Quarter 2025 financial results.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Reach Out

10:00am, Sunday, 04'th May 2025

NEW YORK CITY, NY / ACCESS Newswire / May 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Compa

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Shareholders to Learn More About the Investigation

10:00am, Thursday, 01'st May 2025

NEW YORK CITY, NY / ACCESS Newswire / May 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Compa

Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

09:00am, Thursday, 01'st May 2025

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025.

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

10:00am, Tuesday, 29'th Apr 2025

NEW YORK CITY, NY / ACCESS Newswire / April 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Co

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

10:00am, Thursday, 24'th Apr 2025

NEW YORK CITY, NY / ACCESS Newswire / April 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Co

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect

10:00am, Tuesday, 22'nd Apr 2025

NEW YORK CITY, NY / ACCESS Newswire / April 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Co

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation

10:00am, Sunday, 20'th Apr 2025

NEW YORK CITY, NY / ACCESS Newswire / April 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Co

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by